Drug prices: overcharging claims of Rs 8,447 crore remain unpaid

Why in the News

Medicine makers that overcharge must repay the excess, yet about 84% of the Rs 10,029.8 crore the National Pharmaceutical Pricing Authority (NPPA) has demanded for overcharging remains unpaid. The Rs 8,447.4 crore outstanding surfaces as the Supreme Court presses the government to extend price limits to more medicines.

How does price control work, and how is overcharging recovered?

1. What it is: The Drugs (Prices Control) Order, 2013 (DPCO) is the government order that sets the highest price for listed medicines. It works like a fare cap: charging above it is overcharging.
2. Who enforces it: The NPPA, the government’s drug-price regulator set up in 1997, raises a demand with interest on companies that overcharged. Its records go back to 1979.
3. Trade margin: A seller adds a markup between the price it pays for a medicine and the price the patient pays. That markup is the trade margin.
4. Patients get nothing back: Recovering money from companies is separate from compensating patients. A 2019 Lok Sabha reply said no mechanism exists to compensate consumers, though the NPPA takes consumer complaints.
5. The takeaway: Medicines make up nearly one fifth of a rural hospital bill, yet recovery runs between the regulator and companies, so patients see no refund even when a demand is met.

How much has been recovered, and where is the rest stuck?

1. Recovered: By March 2026 only Rs 1,582.4 crore had been realised, so the unpaid sum is more than five times the amount recovered.
2. Litigation: More than Rs 5,800 crore of the unpaid sum is tied up in court cases.
3. Recovery process: Rs 200 crore relates to cases referred to district collectors for recovery, and Rs 2,369.3 crore is still being processed.
4. Old backlog: Almost half of the unpaid sum dates from cases before 2009.

Why is the Supreme Court pressing for wider price limits?

1. Margin cap: The Centre told the Court it had capped trade margins at 30% for non-scheduled anti-cancer medicines, those outside the ceiling price list.
2. Court’s question: A two judge Bench asked why similar limits cannot cover other medicines and medical products.
3. Price gaps: Citing steep gaps between supply prices and prices charged to patients, the Court asked the government to work out broader measures to regulate medicine prices.
4. Overcharging versus margins: Overcharging beyond regulated prices breaks the DPCO, but a high margin need not be illegal. Both raise costs for patients.
5. Next hearing: The matter will be heard again on October 27.

Challenges

1. Undercounted overcharging: The dues cover only cases the NPPA detected and pursued, so actual overcharging is larger.
2. Uneven enforcement: The number of cases taken up each year peaked in 2015-16 and fell sharply by 2020-21, so pressure on companies is uneven.
3. Narrow price control: Ceiling prices apply only to scheduled medicines on the National List of Essential Medicines, and other medicines face only a cap on yearly price rises.
4. Weak deterrent: When most demanded money stays unpaid for years, overcharging carries little penalty.

Way Forward

1. Priority hearings: The Department of Pharmaceuticals should seek early hearings in the NPPA recovery cases pending in court.
2. Time-bound recovery: Set deadlines for district collectors on cases referred to them for recovery.
3. Patient redress: Build a compensation route for consumers, funded from recovered overcharges.
4. Wider margin cap: Extend a uniform trade margin cap beyond anti-cancer medicines, as the Court has asked the government to examine.
5. Public reporting: The NPPA should publish yearly data on overcharging detected and money recovered.

Conclusion

Price rules bind makers on paper, but the money owed for breaking them has largely not been collected, and none of it reaches patients. The next hearing will show whether the government widens margin control or first strengthens recovery.

Key numbers

1. Before 2009: 731 cases, with Rs 4,764.75 crore demanded and Rs 3,987.5 crore outstanding.
2. Since 2009: About Rs 5,265 crore demanded, of which about Rs 4,460 crore is outstanding.
3. Annual cases: 268 (2015-16), 224 (2017-18), 38 (2020-21), 148 (2022-23) and 133 (2025-26).
4. Medicine spend per hospital stay (2025): Rural Rs 6,368 of Rs 32,884; urban Rs 6,948 of Rs 46,774.

Matching Previous Year Question

“No direct PYQ traced in the provided files. Thematic PYQ: [2015, GS2, 12 marks] For achieving the desired objectives, it is necessary to ensure that the regulatory institutions remain independent and autonomous. Discuss in the light of the experiences in recent past.”